Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance

AIDS

Volumn 22, Issue 2, 2008, Pages 311-313

  De Mendoza, Carmen ^a   Garrido, Carolina ^a   Corral, Angélica ^a   Zahonero, Natalia ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE;

ARTICLE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT FAILURE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CODON; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; POINT MUTATION; PYRIMIDINONES; SPAIN;

EID: 37549063358     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f4244f     Document Type: Article

References (11)

1. Friend J, Parkin N, Liegler T, Martin J, Deeks S. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS 2004; 18:1965-1966.
2. De Mendoza C, Valer L, Bacheler L, Pattery T, Corral A, Soriano V. Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. AIDS 2006; 20:1071-1073.
3. Kagan R, Shenderovich M, Heseltine P, Ramnarayan K, Heseltine P. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir. Protein Sci 2005; 14:1870-1878.
4. Rodes B, Toro C, Sheldon J, Jimenez V, Mansinho K, Soriano V. High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART. AIDS 2006; 20:127-129.
5. Nijhuis M, Wensing A-M, Bierman W, de Jong D, van Rooyen W, Kagan R, et al. A novel genetic pathway involving L76V and M46I leading to lopinavir resistance. Antivir Ther 2007; 12 (suppl):140.
6. Hammer S, Saag M, Schechter M, Montaner J, Schooley R, Jacobsen D, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA panel. JAMA 2006; 296:827-843.
7. Rhee S, Taylor J, Wadhera G, Ben-Hur A, Brutlag D, Shafer R. Genotypic predictors of HIV-1 drug resistance. Proc Natl Acad Sci USA 2006; 103:17355-17360.
8. Johnson V, Brun-Vezinet F, Clotet B, Gunthard H, Kuritzkes D, Pillay D, et al. Update of the drug resistance mutations in HIV-1: Fall 2007. Top HIV Med 2007; 15:119-125.
9. Delaugerre C, Mathez D, Peytavin G, Berthé H, Long K, Galperine T, et al. Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients. AIDS 2007; 21:1210-1213.
10. Kovalevsky A, Liu F, Leshchenko S, Ghosh A, Louis J, Harrison R, et al. Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. J Mol Biol 2006; 363:161-173.
11. Poveda E, De Mendoza C, Martin-Carbonero L, Corral A, Briz V, Soriano V. Prevalence of darunavir-associated resistance mutations in HIV-infected patients mailing other protease inhibitors. J Antimicrob Agents 2007; In press.